Regeneron Offers Free Gene Therapy for Rare Hearing Loss in the U.S., Undecided on Overseas Pricing
Regeneron Pharmaceuticals will provide its newly approved gene therapy Otarmeni for free in the U.S. to treat a rare genetic form of hearing loss, but has not yet decided on pricing for other countries. The decision aligns with a broader agreement with the Trump administration on drug pricing, and the therapy showed 80% effectiveness in clinical trials.
Tickers: $REGN
Topics: drug pricing FDA approval gene therapy hearing loss treatment Regeneron